In one paragraphArticle in The American journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Amitabh ChakDivision of Gastroenterology and Hepatology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-0021-7862 Komal KeerthyDivision of Gastroenterology and Hepatology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0009-0009-9667-6972 Gi-Ming WangCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Wendy BrockDivision of Gastroenterology and Hepatology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0009-0001-7719-1074 Beth BednarchikDivision of Gastroenterology and Hepatology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Rajesh GupthaDivision of Gastroenterology and Hepatology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0009-0004-7772-5664 Suman VermaLucidDx Labs, Lake Forest, California, USA.
Helen MoinovaCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0001-5123-7671 Curtis TatsuokaDivision of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland-Baltimore, Baltimore, Maryland, USA.
John DumotDivision of Gastroenterology and Hepatology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0003-0070-2056 Sapna ThomasDivision of Gastroenterology and Hepatology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Joseph E WillisCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0003-1782-886 Sanford MarkowitzCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0001-5369-5254 Funding
The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Theresa Torres Pizarro · 2015 to 2026
$15.6MPathways of Injury and Repair in Barrett's CarcinogenesisP01CA269019 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI AMITABH CHAK, Kishore Guda · 2023 to 2026
$11.1MIdentify and validate novel epigenetic molecular markers for colorectal neoplasmU01CA152756 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, GUDA, KISHORE · 2010 to 2021
$6.7MValidation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablationU01CA271867 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHETAN BETTEGOWDA, AMITABH CHAK · 2022 to 2026
$4.9MA Clinical Trial of Cancer Prevention by Biomarker Based Detections of Barrett's Esophagus and Its ProgressionR01CA295877 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI AMITABH CHAK, SANFORD D. MARKOWITZ · 2025 to 2026
$3.2MDivision of Cancer Prevention, National Cancer Institute CA269019Division of Cancer Prevention, National Cancer Institute CA271867Division of Cancer Prevention, National Cancer Institute CA295877NCI NIH HHS P01 CA269019NCI NIH HHS R01 CA295877NCI NIH HHS U01 CA152756NCI NIH HHS U01 CA271867NIDDK NIH HHS P30 DK097948
6 · The paper itselfAbstract
introductionUpper endoscopy (EGD) is generally recommended in those with chronic gastroesophageal reflux disease (GERD). To evaluate nonendoscopic screening in those without GERD symptoms.
methodsEsoCheck/Esoguard (LucidDx) was performed in recruited patients without chronic GERD who had ≥3 other BE risk factors.
resultsThe EsoGuard assay was positive in 34 of 120 patients. BE was identified in 9 of 27 who had follow-up EGD, positive predictive value = 33% (17%-54%). EGD performed in 22 of 86 subjects with negative assays found no BE, negative predictive value = 100% (85%-100%). DISCUSSION: Nonendoscopic BE detection is effective in patients without chronic GERD.
Indexed as
Barrett EsophagusAdultAgedEndoscopy, Digestive SystemFemaleGastroesophageal RefluxHumansMaleMiddle AgedPredictive Value of TestsRisk FactorsBarrett's esophagusGERDscreening
Identifiers
PMID40748349
PMCPMC13359468
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390